Mediprogen Has Entered Into Commercial Discussions With Moolec to Expand Their Technology Into the Cosmetics Global Market
Mediprogen Has Entered Into Commercial Discussions With Moolec to Expand Their Technology Into the Cosmetics Global Market
PYEONGCHANG, SOUTH KOREA / ACCESSWIRE / May 9, 2024 / Mediprogen Inc., a company that produces purified protein for the global cosmetics & skincare, pharmaceutical, and industrial protein market through the use of genetically modified soybeans seeds, has signed a non-binding Memorandum of Understanding ("MOU") with Molecular Farming leader Moolec Science S.A. (NASDAQ:MLEC) to engage in a commercial agreement for the use of Moolec's patented Piggy Sooy technology and infrastructure for cosmetics and other non-food global markets.
韓國平昌/ACCESSWIRE/2024年5月9日/通過使用轉基因大豆種子爲全球化妝品和護膚、製藥和工業蛋白市場生產純化蛋白質的公司Moolec Science S.A.（納斯達克股票代碼：MLEC）已與分子農業領導者Moolec Science S.A.（納斯達克股票代碼：MLEC）簽署了一份不具約束力的諒解備忘錄（“諒解備忘錄”），以簽訂使用Moolec Science S.A.（納斯達克股票代碼：MLEC）的商業協議 Olec 爲化妝品和其他非食品全球市場提供的專利 Piggy Sooy 技術和基礎設施。
Mediprogen's Chief Executive Officer, Ph.D Donghern Kim, emphasizes the transformative potential of Plant Molecular Farming technology for the company's goals. He stated: "At Mediprogen, we're committed to pushing boundaries and accelerating our products' journey to market. Our collaboration with Moolec presents an exciting opportunity to leverage cutting-edge technology, ultimately enhancing our strategy across cosmetics: a growing sector from $63.59 billion in 2023 to an estimated $114.32 billion by 2030 at a CAGR of 8.7%."
Mediprogen首席執行官Donghern Kim博士強調了植物分子農業技術對公司目標的變革潛力。他說： “在Mediprogen，我們致力於突破界限，加快產品的上市進程。我們與Moolec的合作爲利用尖端技術提供了一個激動人心的機會，最終加強了我們的化妝品戰略：該行業將從2023年的635.9億美元增長到2030年的估計1143.2億美元，複合年增長率爲8.7％。”
Dr. Kim highlights Moolec's exceptional track record in Molecular Farming, particularly their groundbreaking work with soybeans, showcased through innovations like their patented Piggy Sooy product and recent regulatory approvals. He acknowledges: "Moolec's expertise in this field is unparalleled, and we're thrilled to tap into their wealth of experience. By collaborating with a leader like Moolec, we're poised to replicate their success and pioneer new applications of Molecular Farming technology in diverse industries."
金博士重點介紹了Moolec在分子農業領域的卓越記錄，尤其是他們在大豆領域的開創性工作，這些記錄體現在他們的專利Piggy Sooy產品和最近的監管批准等創新中。他承認： “Moolec在這一領域的專業知識是無與倫比的，我們很高興能利用他們的豐富經驗。通過與像Moolec這樣的領導者合作，我們有望複製他們的成功，開創分子農業技術在不同行業的新應用。”
Concluding, Dr. Kim underscores the mutual benefits of collaboration, pointing out the potential for synergy on both technological and operational fronts. He finishes by affirming: "There's immense potential for us to achieve shared success through collaboration. Together, we can navigate opportunities and challenges, driving innovation and growth for both Mediprogen and Moolec."
最後，金博士強調了合作的互惠互利，指出了技術和運營方面協同增效的潛力。最後，他申明： “我們有通過合作取得共同成功的巨大潛力。我們可以共同應對機遇和挑戰，推動Mediprogen和Moolec的創新和增長。”
The MOU outlines a collaborative research project intended to culminate in a formal commercial agreement for the utilization of Moolec's advanced protein expression technology, specifically the Piggy Sooy platform, in genetically engineered soybeans. The scope of this agreement is tailored towards non-food and animal feed markets, with a primary focus on research, development, manufacturing, and commercialization of products containing specialized non-food molecules derived from soybeans. These products are specifically targeted for application in the cosmetics and skincare industries.
諒解備忘錄概述了一項合作研究項目，該項目旨在最終達成一項正式的商業協議，在基因工程大豆中使用Moolec的先進蛋白質表達技術，特別是Piggy Sooy平台。該協議的範圍是針對非食品和動物飼料市場量身定製的，主要側重於含有源自大豆的特殊非食品分子的產品的研究、開發、製造和商業化。這些產品專門用於化妝品和護膚品行業。
About Mediprogen
關於 Mediprogen
Mediprogen Inc. is a plant biotech venture company which aims to produce valuable cosmetic and pharmaceutical proteins from biotech soybean seeds. Mediprogen uses several plant biotech techniques to improve protein productivity, such as optimizing gene expression vectors and codon usage, etc. The company's target productivity is more than 1% (w/w) seed weight.
Mediprogen Inc. 是一家植物生物技術風險投資公司，旨在利用生物技術大豆種子生產有價值的化妝品和藥物蛋白。Mediprogen使用多種植物生物技術來提高蛋白質生產力，例如優化基因表達載體和密碼子的使用等。該公司的目標生產率爲超過1％（w/w）種子重量。
Contact Information
聯繫信息
Donghern Kim
CEO
donghernk@gmail.com
金東亨
首席執行官
donghernk@gmail.com
Related Files
相關文件
Mediprogen Has Entered into Commercial Discussions With Moolec to Expand their Technology into the Cosmetics Global Market
Mediprogen已與Moolec展開商業討論，以將其技術擴展到全球化妝品市場
SOURCE: Mediprogen Inc.
資料來源：Mediprogen Inc.
譯文內容由第三人軟體翻譯。